ClinicalTrialsFinder
Not Yet RecruitingPhase 2ACTRN12608000013369

Immune regulation and timing of chemotherapy in advanced/recurrent ovarian cancer to evaluate tumour response

Sponsor

Royal Women's Hospital

Enrollment

37 participants

Start Date

Mar 1, 2008

Study Type

Interventional

Conditions

Recurrent Ovarian Cancer

Summary

We have shown that the immune system regulates itself on an approximately 2 week basis.By killing the inhibitory immune cells that prevent immune attack on the tumour using low dose oral chemotherapy it is hoped that tumour cells will die and responses achieved

Eligibility

Sex: FemalesMin Age: 21 Yearss

Plain Language Summary

Simplified for easier understanding

This study is looking at: Immune regulation and timing of chemotherapy in advanced/recurrent ovarian cancer to evaluate tumour response. It is open to women only, aged 21 and older. To take part, you generally need: Rising CA125 (Rustin). There are also some health conditions and factors that may prevent you from joining.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Synchronised chemotherapy using cyclophosphamide 100 mg orally for 3 days each 2 week cycle for at least 3 cycles

Synchronised chemotherapy using cyclophosphamide 100 mg orally for 3 days each 2 week cycle for at least 3 cycles

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000013369

Related Trials

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

NCT0636585340 locations

Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study

NCT074953841 location

Combination Therapy for Recurrent Ovarian Cancer

NCT056107351 location

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT0356434051 locations

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

NCT067694251 location